No-AG deals worse than cash payments in pay-for-delay deals, lawyer says
Reverse payment settlements that involve a branded drug manufacturer agreeing not to release its own generic version have worse competitive effects than deals involving only cash payments, but they may be...To view the full article, register now.
Already a subscriber? Click here to view full article